Wafa et al. designed a cancer vaccine, 20:80 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG):1,6-bis-(p-carboxyphenoxy) hexane (CPH) / OVA, which activated specific CD8 + T cells, produced specific IgG1 antibody, and prevented thymoma formation in mice subcutaneously challenged with a OVA-expressing thymoma cell line [66]. The gene discussed is CD8A; the disease is thymoma.